FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017806482> ?p ?o ?g. }

• W2017806482 endingPage "340" @default.
• W2017806482 startingPage "333" @default.
• W2017806482 abstract "<b><i>Objective:</i></b> To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. <b><i>Methods:</i></b> We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences in median progression-free survival (PFS) for first- (PFS1) and second-line treatment (PFS2), and for the combined PFS (PFS1 plus PFS2) were examined using weighted linear regression. <b><i>Results:</i></b> In the pooled analysis encompassing 853 patients, the median combined PFS for first-line sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months compared with 15.4 months for the reverse sequence (SoSu; 95% CI for difference 1.45–5.12, p = 0.0013). Regarding first-line treatment, no significant difference in PFS1 was noted regardless of which drug was initially used (0.62 months average increase on sorafenib, 95% CI for difference –1.01 to 2.26, p = 0.43). In second-line treatment, sunitinib showed a significantly longer PFS2 than sorafenib (average increase 2.66 months, 95% CI 1.02–4.3, p = 0.003). <b><i>Conclusion:</i></b> The SoSu sequence translates into a longer combined PFS compared to the SuSo sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use." @default.
• W2017806482 created "2016-06-24" @default.
• W2017806482 creator A5013658911 @default.
• W2017806482 creator A5020220564 @default.
• W2017806482 creator A5031517983 @default.
• W2017806482 creator A5047090871 @default.
• W2017806482 creator A5050251508 @default.
• W2017806482 creator A5050931392 @default.
• W2017806482 creator A5052238969 @default.
• W2017806482 creator A5071589424 @default.
• W2017806482 creator A5084321651 @default.
• W2017806482 creator A5086971449 @default.
• W2017806482 creator A5090509109 @default.
• W2017806482 creator A5090761384 @default.
• W2017806482 creator A5091335397 @default.
• W2017806482 date "2012-01-01" @default.
• W2017806482 modified "2023-09-27" @default.
• W2017806482 title "A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma" @default.
• W2017806482 cites W1520255941 @default.
• W2017806482 cites W1522152077 @default.
• W2017806482 cites W1762785158 @default.
• W2017806482 cites W1965874702 @default.
• W2017806482 cites W1970600886 @default.
• W2017806482 cites W1999966467 @default.
• W2017806482 cites W2002469074 @default.
• W2017806482 cites W2013969274 @default.
• W2017806482 cites W2017840916 @default.
• W2017806482 cites W2019607817 @default.
• W2017806482 cites W2023952988 @default.
• W2017806482 cites W2031152150 @default.
• W2017806482 cites W2036434473 @default.
• W2017806482 cites W2070019048 @default.
• W2017806482 cites W2078449820 @default.
• W2017806482 cites W2099088585 @default.
• W2017806482 cites W2100669312 @default.
• W2017806482 cites W2106787323 @default.
• W2017806482 cites W2110720470 @default.
• W2017806482 cites W2118677643 @default.
• W2017806482 cites W2122538070 @default.
• W2017806482 cites W2142297664 @default.
• W2017806482 cites W2153867442 @default.
• W2017806482 cites W2162424705 @default.
• W2017806482 cites W2166189454 @default.
• W2017806482 cites W2241079867 @default.
• W2017806482 cites W2282119373 @default.
• W2017806482 doi "https://doi.org/10.1159/000338001" @default.
• W2017806482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22677881" @default.
• W2017806482 hasPublicationYear "2012" @default.
• W2017806482 type Work @default.
• W2017806482 sameAs 2017806482 @default.
• W2017806482 citedByCount "32" @default.
• W2017806482 countsByYear W20178064822012 @default.
• W2017806482 countsByYear W20178064822013 @default.
• W2017806482 countsByYear W20178064822014 @default.
• W2017806482 countsByYear W20178064822015 @default.
• W2017806482 countsByYear W20178064822016 @default.
• W2017806482 countsByYear W20178064822017 @default.
• W2017806482 countsByYear W20178064822019 @default.
• W2017806482 countsByYear W20178064822020 @default.
• W2017806482 crossrefType "journal-article" @default.
• W2017806482 hasAuthorship W2017806482A5013658911 @default.
• W2017806482 hasAuthorship W2017806482A5020220564 @default.
• W2017806482 hasAuthorship W2017806482A5031517983 @default.
• W2017806482 hasAuthorship W2017806482A5047090871 @default.
• W2017806482 hasAuthorship W2017806482A5050251508 @default.
• W2017806482 hasAuthorship W2017806482A5050931392 @default.
• W2017806482 hasAuthorship W2017806482A5052238969 @default.
• W2017806482 hasAuthorship W2017806482A5071589424 @default.
• W2017806482 hasAuthorship W2017806482A5084321651 @default.
• W2017806482 hasAuthorship W2017806482A5086971449 @default.
• W2017806482 hasAuthorship W2017806482A5090509109 @default.
• W2017806482 hasAuthorship W2017806482A5090761384 @default.
• W2017806482 hasAuthorship W2017806482A5091335397 @default.
• W2017806482 hasConcept C121608353 @default.
• W2017806482 hasConcept C126322002 @default.
• W2017806482 hasConcept C143998085 @default.
• W2017806482 hasConcept C2777472916 @default.
• W2017806482 hasConcept C2778019345 @default.
• W2017806482 hasConcept C2778695046 @default.
• W2017806482 hasConcept C2778820342 @default.
• W2017806482 hasConcept C2779490328 @default.
• W2017806482 hasConcept C2780739268 @default.
• W2017806482 hasConcept C3019894029 @default.
• W2017806482 hasConcept C71924100 @default.
• W2017806482 hasConcept C98274493 @default.
• W2017806482 hasConceptScore W2017806482C121608353 @default.
• W2017806482 hasConceptScore W2017806482C126322002 @default.
• W2017806482 hasConceptScore W2017806482C143998085 @default.
• W2017806482 hasConceptScore W2017806482C2777472916 @default.
• W2017806482 hasConceptScore W2017806482C2778019345 @default.
• W2017806482 hasConceptScore W2017806482C2778695046 @default.
• W2017806482 hasConceptScore W2017806482C2778820342 @default.
• W2017806482 hasConceptScore W2017806482C2779490328 @default.
• W2017806482 hasConceptScore W2017806482C2780739268 @default.
• W2017806482 hasConceptScore W2017806482C3019894029 @default.
• W2017806482 hasConceptScore W2017806482C71924100 @default.
• W2017806482 hasConceptScore W2017806482C98274493 @default.
• W2017806482 hasIssue "6" @default.

• next